PODD vs. ABMD, PEN, IRTC, EW, DXCM, IDXX, RMD, STE, HOLX, and BAX
Should you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Abiomed (ABMD), Penumbra (PEN), iRhythm Technologies (IRTC), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), STERIS (STE), Hologic (HOLX), and Baxter International (BAX). These companies are all part of the "medical" sector.
Abiomed (NASDAQ:ABMD) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.
Insulet has higher revenue and earnings than Abiomed. Insulet is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.
Insulet received 179 more outperform votes than Abiomed when rated by MarketBeat users. Likewise, 66.05% of users gave Insulet an outperform vote while only 61.49% of users gave Abiomed an outperform vote.
Insulet has a consensus price target of $239.18, suggesting a potential upside of 20.94%. Given Abiomed's higher probable upside, analysts plainly believe Insulet is more favorable than Abiomed.
94.5% of Abiomed shares are owned by institutional investors. 2.5% of Abiomed shares are owned by insiders. Comparatively, 0.5% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Insulet had 22 more articles in the media than Abiomed. MarketBeat recorded 22 mentions for Insulet and 0 mentions for Abiomed. Abiomed's average media sentiment score of 0.99 beat Insulet's score of 0.44 indicating that Insulet is being referred to more favorably in the news media.
Abiomed has a net margin of 24.84% compared to Abiomed's net margin of 13.14%. Abiomed's return on equity of 34.06% beat Insulet's return on equity.
Abiomed has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Insulet has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.
Summary
Insulet beats Abiomed on 9 of the 17 factors compared between the two stocks.
Get Insulet News Delivered to You Automatically
Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
